<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186120</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0036</org_study_id>
    <nct_id>NCT01186120</nct_id>
  </id_info>
  <brief_title>Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions</brief_title>
  <acronym>LONG-DES-V</acronym>
  <official_title>Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-V:Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study is a multi-center, randomized, study to compare the efficacy of
      biolimus A9-eluting stent (Nobori) vs. everolimus-eluting stent (Promus Element) for long
      coronary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following angiography, patients with significant diameter stenosis &gt;50% and lesion length(&gt;
      25mm) requiring single or multiple long-stent placement(total stent length 28mm) by visual
      estimation and eligible for LONG-DES V trial inclusion and exclusion criteria will be
      randomized 1:1 to a) NOBORI and b) PROMUS-ELEMENT stent by the stratified randomization
      method.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late luminal loss</measure>
    <time_frame>9 month angiographic follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause and cardiac)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis(ARC criteria)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>at 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause and cardiac)</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause and cardiac)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or MI</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or MI</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death or MI</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death or MI</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death or MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis(ARC criteria)</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis(ARC criteria)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss</measure>
    <time_frame>9 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8. Target-vessel failure (death from any cause, myocardial infarction, and ischemic-driven target-vessel revascularization)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment restenosis</measure>
    <time_frame>9 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic pattern of restenosis</measure>
    <time_frame>9 month angiographic follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus A9-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NOBORI stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PROMUS ELEMENTE stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus A9-eluting stent</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>Biolimus A9-eluting stent</arm_group_label>
    <other_name>NOBORI stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <other_name>PROMUS ELEMENT stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be at least 18 years of age.

          -  Significant native coronary artery stenosis (&gt;50% by visual estimate) with lesion
             length of more than 25mm, which requiring single or multiple long stent placement
             (&gt;=28mm)

          -  Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation
             myocardial infarction

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  Any contraindication to any of the following medications: aspirin, heparin,
             clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus.

          -  An elective surgical procedure is planned that would necessitate interruption of
             antiplatelet drugs during the first 6 months post enrollment.

          -  Acute ST-segment-elevation MI or cardiogenic shock

          -  Terminal illness with life expectancy &lt;1 year

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.

          -  In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent
             segment, non-target vessel ISR is permitted) Patients with EF&lt;30%.

          -  Serum creatinine level &gt;=3.0mg/dL or dependence on dialysis.

          -  Patients with left main stem stenosis (&gt;50% by visual estimate).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital, Buchen</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chooncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University, Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>coronary disease</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Umirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

